Remission Through Early Monitored Insulin Therapy - Duration Month
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
REMIT-DM is a feasibility pilot study where participants will be recruited soon after their
diagnosis of type 2 diabetes to be placed immediately on insulin therapy for maximum of four
weeks with titrations of insulin guided by glucose levels and trends provided by a continuous
glucose monitor (CGM), with the purpose of achieving diabetes remission.